Natera, Inc. services

Your Oncology Support Resource. At Natera, a test is more than just a test; it’s part of an integrated experience, built around a core suite of services to support patients and providers and to make testing easy.

Why partner with Signatera for your clinical trial? Clinically validated across multiple solid tumors, Signatera has shown to predict relapse in >98% of patients without further treatment. Experienced team with Global reach: CE Mark, three FDA Breakthrough Device Designations, 8 Non-Significant Risk (NSR) determinations. >60 Natera IP assets covering ctDNA MRD and monitoring.